Autologous hematopoietic cell transplantation for multiple sclerosis: A systematic review

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 204-213

  Reston, James T ^a   Uhl, Stacey ^a   Treadwell, Jonathan R ^a   Nash, Richard A ^b   Schoelles, Karen ^a  

^a ECRI INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

meta analysis; multiple sclerosis; progressive; stem cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; THYMOCYTE ANTIBODY;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; DRUG MEGADOSE; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; MYELOABLATIVE CONDITIONING; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 79951548112     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510383609     Document Type: Review

References (32)

1. Peterson JW and Trapp BD Neuropathobiology of multiple sclerosis. Neurol Clin 2005 ; 23: 107-129, vi - vii. (Pubitemid 40126917)
2. National MS Society. The disease-modifying drugs. Newly diagnosed, 2008. Available at: http://www.nationalmssociety.org/download.aspx?id=45.
3. Oksenberg JR and Hauser SL Genetics of multiple sclerosis. Neurol Clin 2005 ; 23: 61-75, vi. (Pubitemid 40126915)
4. Mancardi G. and Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008 ; 7: 626-636.
5. Atkins H. and Freedman M. Immunoablative therapy as a treatment aggressive multiple sclerosis. Neurol Clin 2005 ; 23: 273-300, ix. (Pubitemid 40126925)
6. Griffith LM, Pavletic SZ, Tyndall A., Bredeson CN, Bowen JD, Childs RW, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-sponsored international workshop. Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005 ; 11: 862-870. (Pubitemid 41655668)
7. Treadwell JT, Tregear SJ, Reston JT and Turkelson CM A system for rating the stability and strength of medical evidence. BMC Med Res Methodol 2006 ; 6: 52. Available at: http://www.biomedcentral.com/1471-2288/6/52.
8. DerSimonian R. and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 ; 7: 177-188. (Pubitemid 17189972)
9. Borenstein M., Hedges L., Higgins J. and Rothstein H. Comprehensive Meta-analysis, Version 2. Englewood Cliffs, NJ: Biostat, 2005. Available at: http://www.meta-analysis.com/pages/about-us.html.
10. Borenstein M., Hedges L., Higgins J. and Rothstein H. Introduction to Meta-analysis. Hoboken, NJ: John Wiley & Sons, Inc, 2009.
11. Higgins JP, Thompson SG, Deeks JJ and Altman DG Measuring inconsistency in meta-analyses. BMJ 2003 ; 327: 557-560. (Pubitemid 37088507)
12. Higgins JP and Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002 ; 21: 1539-1558. (Pubitemid 34746062)
13. Higgins JP and Thompson SG Controlling the risk of spurious findings from meta-regression. Stat Med 2004 ; 23: 1663-1682. (Pubitemid 38765338)
14. Ni XS, Ouyang J., Zhu WH, Wang C. and Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006 ; 20: 485-489. (Pubitemid 43983828)
15. Xu J., Ji BX, Su L., Dong HQ, Sun XJ and Liu CY Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl) 2006 ; 119: 1851-1855. (Pubitemid 44816860)
16. Saccardi R., Mancardi GL, Solari A., Bosi A., Bruzzi P., Di Bartolomeo P., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005 ; 105: 2601-2607. (Pubitemid 40387065)
17. Capello E., Saccardi R., Murialdo A., Gualandi F., Pagliai F., Bacigalupo A., et al. Italian GITMO-Neuro Intergroup on ASCT for Multiple Sclerosis. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci 2005 ; 26 (Suppl 4). S200 - S203.
18. Saiz A., Blanco Y., Carreras E., Berenguer J., Rovira M., Pujol T., et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 2004 ; 62: 282-284. (Pubitemid 38167140)
19. Carreras E., Saiz A., Marin P., Martinez C., Rovira M., Villamor N., et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003 ; 88: 306-314. (Pubitemid 36358719)
20. Fassas A., Anagnostopoulos A., Kazis A., Kapinas K., Sakellari I., Kimiskidis V., et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 2000 ; 20: 24-30. (Pubitemid 30210103)
21. Samijn JP, te Boekhorst PA, Mondria T., van Doom PA, Flach HZ, van der Meche FG, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006 ; 77: 46-50. (Pubitemid 43022689)
22. Burt RK, Cohen BA, Russell E., Spero K., Joshi A., Oyama Y., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003 ; 102: 2373-2378. (Pubitemid 37193572)
23. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003 ; 102: 2364-2372. (Pubitemid 37193571)
24. Fagius J., Lundgren J. and Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009 ; 15: 229-237.
25. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008 ; 36: 922-928.
26. Saccardi R., Kozak T., Bocelli-Tyndall C., Fassas A., Kazis A., Havrdova E., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006 ; 12: 814-823. (Pubitemid 46111776)
27. Espigado I., Marin-Niebla A., Rovira M., Julia A., Rodriguez JM, Altes A., et al. Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience. Transplant Proc 2003 ; 35: 742-743. (Pubitemid 36338139)
28. Kozak T., Havrdova E., Pit'ha J., Gregora E., Pytlik R., Maaloufova J., et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc 2001 ; 33: 2179-2181. (Pubitemid 33762676)
29. Openshaw H., Lund BT, Kashyap A., Atkinson R., Sniecinski I., Weiner LP, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000 ; 6: 563-575.
30. Fassas A., Passweg JR, Anagnostopoulos A., Kazis A., Kozak T., Havrdova E., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002 ; 249: 1088-1097. (Pubitemid 35002235)
31. Burt RK, Loh Y., Pearce W., Beohar N., Barr WG, Craig R., et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008 ; 299: 925-936. (Pubitemid 351397068)
32. Joy JE, Johnston Jr RB (Eds) Multiple Sclerosis: Current Status and Strategies for the Future. National Academy Press, 2001.